Profile of ranibizumab: efficacy and safety for the treatment of wet age-related macular degeneration
Youxin Chen, Fei HanDepartment of Ophthalmology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, ChinaAbstract: Wet age-related macular degeneration (AMD) causes severe vision loss due to the development of choroidal neovasculariz...
Main Authors: | Chen Y, Han F |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2012-07-01
|
Series: | Therapeutics and Clinical Risk Management |
Online Access: | http://www.dovepress.com/profile-of-ranibizumab-efficacy-and-safety-for-the-treatment-of-wet-ag-a10361 |
Similar Items
-
Clinical efficacy of Ranibizumab in the treatment of wet age-related macular degeneration
by: Ling-Jun Wei, et al.
Published: (2017-12-01) -
Effect of conbercept or ranibizumab in the treatment of wet age-related macular degeneration
by: Dawei Zhang, et al.
Published: (2019-01-01) -
Comparison of efficacy between Ranibizumab and Conbercept for wet age-related macular degeneration
by: Qiang Fan, et al.
Published: (2018-08-01) -
Ranibizumab with transpupillary thermotherapy for clinical efficacy in wet age-related macular degeneration
by: Jia Li, et al.
Published: (2014-10-01) -
Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration
by: Dervenis N, et al.
Published: (2016-06-01)